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Abstract
Background The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients.
Objective This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity 
of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients with advanced solid 
tumors and defined the recommended Phase II dose.
Patients and methods Nineteen patients received adavosertib 175 mg twice daily (bid) for 2.5 days (five doses) in combina-
tion with carboplatin (AUC 5) alone or paclitaxel (175 mg/m2) plus carboplatin, or adavosertib 225 mg bid for 2.5 days in 
combination with paclitaxel plus carboplatin in 21-day cycles. Preliminary safety and dose-limiting toxicity analyses were 
performed and dose escalation/de-escalation conducted as appropriate.
Results Adavosertib 175 mg bid for 2.5 days with carboplatin alone or paclitaxel plus carboplatin was considered tolerable. 
Two patients receiving adavosertib 225 mg bid in combination with paclitaxel plus carboplatin experienced dose-limiting 
toxicities (grade 4 sepsis; grade 5 acute respiratory distress syndrome); this regimen was not considered tolerable. Grade ≥ 3 
adverse events reported most commonly in any cohort included: anemia; decreased white blood cell count; decreased neu-
trophil count; neutropenia; decreased platelet count; thrombocytopenia; and febrile neutropenia. Exposure to adavosertib, 
as determined by pharmacokinetic analysis, in Asian patients was higher than that previously seen in Western patients. A 
partial response occurred in 2/12 evaluable patients (16.7%) at the recommended Phase II dose.
Conclusions Adavosertib 175 mg bid for 2.5 days was chosen as the recommended Phase II dose in combination with pacli-
taxel and carboplatin in Asian patients.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1152 3-020-00701 -5) contains 
supplementary material, which is available to authorized users.
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1 Introduction
The tyrosine kinase WEE1 regulates cyclin-dependent kinase 
1 (CDK1), which drives cells from the G2 phase into mitosis, 
and CDK2, which drives cells into and through the S phase 
of the cell cycle [1, 2]. The tumor suppressor protein p53 is 
involved in regulation of the G1 checkpoint. Many human 
cancers have loss-of-function TP53 mutations, meaning that 
they become more dependent on the G2/M- and S-phase 
checkpoints to halt progression of the cell cycle [3, 4].
Following DNA damage, WEE1 inhibits CDK1, leading 
to cell cycle arrest and allowing time for DNA repair [4]. 
Inhibiting WEE1 abrogates G2 cell cycle arrest, resulting 
in premature entry into mitosis and leading to aberrantly 
high CDK2 activity in S-phase cells, with the deregulated 
DNA replication resulting in replication stress [1, 5]. WEE1 
inhibition also exploits the G1 checkpoint deficiency seen 
in p53-deficient cells [3]. Thus, WEE1 inhibition sensitizes 
tumor cells to DNA-damaging chemotherapy and can lead to 
unstable DNA replication, DNA damage and mitotic catas-
trophe [1, 3].
Adavosertib (AZD1775) is a first-in-class, potent, selec-
tive WEE1 inhibitor. Adavosertib showed acceptable toxic-
ity, linear pharmacokinetics, and target engagement when 
administered in combination with cisplatin, carboplatin, 
or gemcitabine in patients with advanced solid tumors in a 
Phase I study (NCT00648648, PN001) [6].
76 H. Kato et al.
Key Points 
Adavosertib 175 mg twice daily (bid) for 2.5 days (five 
doses) in combination with carboplatin (AUC 5) alone or 
paclitaxel (175 mg/m2) plus carboplatin was considered 
tolerable in Asian patients with advanced solid tumors.
Exposure to adavosertib, as determined by pharmacoki-
netic analysis, was 30–45% higher in Asian patients than 
that previously seen in Western patients.
In Asian patients, the recommended Phase II dose of 
adavosertib (175 mg bid for 2.5 days in combination 
with paclitaxel plus carboplatin) is lower than the recom-
mended Phase II dose in Western patients, most likely 
reflecting the increased exposure of adavosertib in Asian 
patients.
solid tumor (excluding lymphoma), failure to respond to 
standard therapy, disease progression despite standard ther-
apy, or cancers for which standard therapy did not exist. 
Patients also had to have at least one measurable lesion that 
could be accurately assessed at baseline by computed tomog-
raphy or magnetic resonance imaging and Response Evalua-
tion Criteria in Solid Tumors (RECIST) v1.1. Patients were 
required to have an absolute neutrophil count ≥ 1.5 × 109/L, 
hemoglobin ≥ 90 g/L, platelets ≥ 100 × 109/L, alanine ami-
notransferase and aspartate aminotransferase ≤ 2.5 × the 
upper limit of normal (ULN) or ≤ 5 × ULN if there were 
known hepatic metastases, and total bilirubin ≤ 1.25 × ULN 
or total bilirubin ≤ 3.0 × ULN with documented Gilbert’s 
syndrome (unconjugated hyperbilirubinemia). Patients who 
had undergone radiotherapy with a limited field of radia-
tion for palliation within 1 week of the first dose of study 
treatment, with the exception of patients receiving radiation 
to > 30% of the bone marrow, or with a wide field of radia-
tion within 4 weeks of the first dose of study treatment were 
excluded from the study, as were patients with refractory 
nausea and vomiting. Full eligibility criteria are summarized 
in the Supplementary Material.
2.2  Study Design and Treatment
This non-randomized, open-label, multicenter, Phase Ib 
study was conducted in seven centers in Australia, Japan, 
and South Korea.
Patients were initially recruited into cohorts 1 and 1a, 
with three to six patients planned for each cohort. Based on 
the data from earlier studies [6, 10], patients in these cohorts 
received a single starting dose of oral adavosertib 175 mg on 
day 1 (cycle 0) (Fig. 1 and Supplementary Material). This 
was followed 5 ± 2 days later by adavosertib 175 mg bid 
for 2.5 days (five doses) in combination with intravenous 
paclitaxel (175 mg/m2 as a 3-h infusion on day 1) plus intra-
venous carboplatin (AUC 5 on day 1) (cohort 1; A175PC) 
or carboplatin alone (AUC 5 on day 1) (cohort 1a; A175C) 
in subsequent 21-day cycles.
Preliminary safety and dose-limiting toxicity (DLT) anal-
yses were performed and dose-escalation/de-escalation con-
ducted as appropriate (Supplementary Material). A DLT was 
defined as an adverse event or abnormal laboratory value 
that occurred from the first dose of study treatment up to 
the last day of cycle 1. Dose increases were permitted after 
review of data from a minimum of three evaluable patients. 
If no DLT was observed in a cohort of three to six evaluable 
patients, then dose escalation could occur. Based on these 
assessments, a planned three to six patients were recruited 
in a dose-escalation cohort (cohort 2) in which they received 
a single dose of adavosertib 225 mg in cycle 0, followed 
5 ± 2 days later by adavosertib 225 mg bid for 2.5 days in 
combination with paclitaxel plus carboplatin in subsequent 
In Phase II studies, adavosertib showed antitumor 
activity when administered in combination with carbopl-
atin in women with TP53-mutated ovarian cancer refrac-
tory or resistant to first-line platinum-based chemother-
apy (NCT01164995, PN009) [7], or in combination with 
paclitaxel plus carboplatin in women with TP53-mutated 
platinum-sensitive ovarian cancer (NCT01357161, PN004) 
[8]. In study PN004, progression-free survival was longer 
in patients receiving adavosertib with paclitaxel plus carbo-
platin than in those receiving placebo with paclitaxel plus 
carboplatin [8].
A Phase I study established a maximum tolerated dose 
of adavosertib of 225 mg twice daily (bid) for 2.5 days 
(five doses; day 1, day 2, and the morning of day 3) per 
21-day cycle when administered as monotherapy to Western 
patients with advanced solid tumors (NCT01748825) [9]. 
In Western patients, the recommended Phase II regimen of 
adavosertib for use in combination with paclitaxel (175 mg/
m2) and carboplatin (AUC 5) is also 225 mg bid for 2.5 days 
per 21-day cycle, which was used successfully in the PN004 
study [8]. The aim of this Phase Ib study (NCT02341456) 
was to evaluate the safety and tolerability of the combination 
of adavosertib with carboplatin alone or with paclitaxel plus 
carboplatin in Asian patients with advanced solid tumors 
and to define the recommended Phase II dose. It is the first 
study to investigate this treatment regimen in this patient 
population.
2  Methods
2.1  Patient Selection
Eligibility criteria included patients who had histologic or 
cytologic confirmation of a locally advanced or metastatic 
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cycles (A225PC). If two or more patients experienced a DLT 
in a group of up to six patients, irrespective of the number 
of patients enrolled, the dose was considered not tolerated 
and recruitment to the cohort and dose escalation ceased. A 
lower intermediary dose (de-escalation) could be considered 
in order to better define the combination recommended dose 
for further clinical evaluation (Supplementary Material).
After six cycles, patients in cohorts 1 and 2 could con-
tinue adavosertib monotherapy, whereas patients in cohort 
1a continued combination therapy until disease progression 
or unacceptable toxicity.
An additional three to six patients could be recruited to 
the cohort in which the recommended combination dose was 
defined for further evaluation of the safety, tolerability, and 
pharmacokinetics of adavosertib.
Pre-medication with antiemetics (excluding aprepitant) 
was allowed.
The study was performed in accordance with the Declara-
tion of Helsinki, Good Clinical Practice, applicable regula-
tory requirements, and the AstraZeneca policy on bioethics 
[11]. The institutional review boards or independent ethics 
committees of all investigational sites approved the protocol, 
and all patients provided written, informed consent.
2.3  Study Objectives
The primary objective was to assess the safety and toler-
ability of adavosertib in combination with carboplatin or 
paclitaxel plus carboplatin. Secondary objectives were to 
characterize the pharmacokinetic profiles of adavosertib 
(after single dosing and at steady state after multiple dosing 
with carboplatin or paclitaxel plus carboplatin), paclitaxel 
(in combination with adavosertib and carboplatin) and car-
boplatin (in combination with adavosertib or adavosertib 
and paclitaxel). An additional secondary objective was to 
obtain a preliminary assessment of the antitumor activity of 
adavosertib in combination with carboplatin alone or with 
paclitaxel plus carboplatin.
2.4  Assessments
Adverse events (AEs) were monitored throughout the study 
until the end of the follow-up period (28 ± 7 days after study 
treatment was discontinued or completed) and were graded 
using the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (v4.03). Laboratory parameters, 
electrocardiogram (ECG) changes, and vital signs were also 
monitored. Hematology laboratory evaluations were per-
formed at screening, on day 1 of cycle 0, and on days 1, 8, 
and 15 for cycles 1 and beyond. Coagulation laboratory eval-
uations were performed at screening and on day 1 of every 
Cycles 1– 6
Patients could 
continue 
adavosertib 
monotherapy in 
the absence of 
discontinuation 
criteria at the 
investigator’s 
discretion
Cohort 1
Adavosertib 175 mg bid for 2.5 days per 
cycle, paclitaxel 175 mg/m², carboplatin 
AUC 5 in 21-day cycles
After 6 cycles
Cohort 2 
Adavosertib 225 mg bid for 2.5 days per 
cycle, paclitaxel 175 mg/m², carboplatin 
AUC 5 in 21-day cycles
Cohort 1a 
Adavosertib 175 mg bid for 2.5 days per 
cycle, carboplatin AUC 5 in 21-day cycles
Patients continued 
combination therapy 
until disease 
progression or 
unacceptable toxicity
5 ± 2 days 
washout
Cycle 0
Cohort 1
Adavosertib 175 mg
Cohort 2
Adavosertib 225 mg
Cohort 1a 
Adavosertib 175 mg
Fig. 1  Treatment cohorts. Patients were initially recruited into 
cohorts 1 and 1a, with 3–6 patients planned for each cohort. Based on 
safety and dose-limiting toxicity assessments, a planned 3–6 patients 
were then recruited in a dose-escalation cohort (cohort 2). An addi-
tional 3–6 patients could be recruited to the cohort in which the rec-
ommended combination dose was defined for further evaluation of 
the safety, tolerability and pharmacokinetics of adavosertib. bid twice 
daily
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cycle. Chemistry laboratory evaluations were performed at 
screening, on day 1 of cycle 0, on days 1 and 15 of cycle 1, 
and on day 1 of each additional 21-day cycle.
Blood samples for pharmacokinetic analysis of ada-
vosertib were collected pre-dose and up to 8 h post-dose 
on: cycle 0, day 1 following a single dose; cycle 1, day 1 
following a single dose in combination with chemotherapy; 
and cycle 1, day 3 following multiple doses in combination 
with chemotherapy (Supplementary Material). Additional 
samples were collected pre-dose at day 3 of odd-numbered 
cycles. Plasma concentrations of adavosertib were deter-
mined by using a validated liquid chromatography–tandem 
mass spectrometry assay with a lower limit of quantitation 
of 2 ng/mL.
Blood samples for pharmacokinetic analysis of pacli-
taxel and carboplatin were collected pre-dose and up to 8 h 
after the start of infusion at cycle 1, day 1 (Supplementary 
Material).
Response was evaluated according to RECIST v1.1 at 
screening and then at cycle 1, day 1 and every 6 weeks there-
after (at Japanese sites, an additional assessment occurred 
at cycle 2, day 1).
2.5  Statistical Analysis
To assess the tolerability of adavosertib in combination with 
chemotherapy, cohorts of at least six evaluable patients were 
required, with an expected sample size of approximately 18 
patients per combination therapy.
The safety analysis set comprised all patients who 
received at least one dose of adavosertib, paclitaxel, or car-
boplatin, the pharmacokinetic analysis set comprised dosed 
patients for whom an adequate pharmacokinetic profile had 
been obtained, and the tumor-response analysis set com-
prised dosed patients with measurable disease at baseline.
Safety assessments, pharmacokinetic parameters, and 
tumor response were analyzed by descriptive statistics.
3  Results
3.1  Patient Characteristics
Seven, six, and six patients were treated in cohorts 1, 2, and 
1a, respectively. One patient in cohort 1 was recruited in 
error (without measurable disease); data from this patient 
were used in the safety and pharmacokinetic analyses but 
excluded from the tumor response analyses. One patient 
in cohort 2 and one in cohort 1a were still receiving study 
treatment at data cut-off (14 December 2016); the patient 
in cohort 2 was receiving adavosertib monotherapy. All 
patients were of Asian descent; patient baseline character-
istics are shown in Table 1.
Exposure to adavosertib, paclitaxel, and carboplatin is 
summarized in Supplementary Table S1. There were no ada-
vosertib dose reductions during cycle 0 or 1, and no pacli-
taxel or carboplatin dose reductions during cycle 1. After 
cycle 1, adavosertib dose reductions occurred in three of six 
patients (50.0%) from cohort 2, paclitaxel dose reductions 
occurred in two of seven patients (28.6%) from cohort 1 and 
three of six patients (50.0%) from cohort 2, and carboplatin 
dose reductions occurred in one of seven patients (14.3%) 
from cohort 1, four of six patients (66.7%) from cohort 2, 
and one of six patients (16.7%) from cohort 1a.
3.2  Safety and Tolerability
DLTs (grade 4 decreased platelet count) occurred in one 
patient each in cohorts 1 and 1a. Two patients in cohort 2 
experienced DLTs (grade 4 sepsis and grade 5 acute respira-
tory distress syndrome).
Treatment-emergent adverse events (TEAEs) reported in 
at least one patient after a single dose of adavosertib were 
nausea (three of 19 [15.8%] patients), constipation (one 
[5.3%] patient), diarrhea (one [5.3%] patient), and hypersen-
sitivity (one [5.3%] patient). All of these TEAEs were grade 
1 and none occurred in more than one patient in each cohort.
With combination therapy, the most commonly reported 
TEAEs (all grades) included nausea, vomiting, anemia, diar-
rhea, and decreased white blood cell (WBC) count (Table 2). 
Hematologic AEs were the most commonly reported 
grade ≥ 3 TEAEs (Table 2). The incidence of TEAEs (all 
grades and grade ≥ 3) was generally highest in cohort 2 and 
lowest in cohort 1a. The small number of patients in each 
cohort should be considered when interpreting the incidence 
of TEAEs.
The most commonly occurring TEAEs (incidence 
of > 50% in any cohort) considered by the investigator as 
being potentially related to treatment were nausea (85.7%, 
83.3%, and 50.0% of patients in cohorts 1, 2, and 1a, 
respectively), diarrhea (71.4%, 83.3%, and 33.3%), vomit-
ing (71.4%, 66.7%, and 33.3%), anemia (71.4%, 66.7%, and 
33.3%), decreased WBC count (71.4%, 83.3%, and 50.0%), 
and decreased platelet count (57.1%, 50.0%, and 33.3%).
Fatal TEAEs were reported in one patient each in cohorts 
1 and 2 (Table 2). The patient from cohort 1 had abnormal 
hepatic function resulting in liver failure and death. This 
patient had advanced head and neck cancer with tumors 
in the liver and a history of hepatomegaly. Extensive liver 
metastases were documented on day 15 of cycle 5, and the 
patient died on day 19 of cycle 5. The investigator attributed 
death “almost certainly” to disease progression and consid-
ered the event to be unrelated to adavosertib. The patient 
from cohort 2 had acute respiratory distress syndrome in 
association with interstitial pneumonia, which was consid-
ered by the investigator to be possibly related to adavosertib 
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and paclitaxel. This patient had advanced lung cancer with 
previous tomotherapy to the lung and prior left upper lung 
lobectomy and was hospitalized and died on day 5 of cycle 
1.
Serious TEAEs were reported in seven patients in cohorts 
1 and 2 (Table 2). Six patients had serious AEs considered 
to be causally related to adavosertib: nausea and vomiting 
in one patient (cohort 1); decreased platelet count in one 
patient (cohort 1); neutropenia in one patient (cohort 2); 
febrile neutropenia in one patient each in cohorts 1 and 2; 
and diarrhea, acute respiratory distress syndrome, and inter-
stitial pneumonia in one patient (cohort 2).
TEAEs resulted in discontinuation of adavosertib in one 
patient (14.3%) from cohort 1 (micturition urgency, nau-
sea, and vomiting) and two patients (33.3%) from cohort 
2 (febrile neutropenia in one patient and acute respiratory 
distress syndrome, interstitial pneumonia, and diarrhea 
in a second patient). Paclitaxel was discontinued because 
of TEAEs in one patient (14.3%) from cohort 1 and two 
patients (33.3%) from cohort 2, and carboplatin was dis-
continued because of TEAEs in two patients (33.3%) from 
cohort 2.
No trends were observed in vital signs over time, 
and there were no clinically important changes in ECG 
recordings.
3.3  Pharmacokinetic Profile
Adavosertib was steadily absorbed, with a median time to 
maximum plasma concentration (tmax) of 2.02–4.04 h, and then 
slowly eliminated (Fig. 2 and Table 3). After reaching the max-
imum plasma concentration (Cmax), adavosertib concentrations 
Table 1  Patient baseline characteristics
A175C adavosertib 175 mg + carboplatin, A175PC adavosertib 175 mg + paclitaxel + carboplatin, A225PC adavosertib 225 mg + paclitaxel + car-
boplatin
a Including cancer of the nasopharynx, larynx, and trachea
b Including stomach cancer (n = 1), pancreatic cancer (n = 1), skin/soft tissue cancer (n = 1), lung cancer (n = 1), thymic cancer (n = 2), and gall-
bladder cancer (n = 1)
Cohort 1 (A175PC)
N = 7
Cohort 2 (A225PC)
N = 6
Cohort 1a (A175C)
N = 6
Age, years
 Median (min, max) 55.0 (46, 62) 57.0 (34, 66) 49.5 (19, 56)
Race, n (%)
 Asian 7 (100) 6 (100) 6 (100)
Sex, n (%)
 Male 4 (57.1) 1 (16.7) 3 (50.0)
 Female 3 (42.9) 5 (83.3) 3 (50.0)
Type of cancer, n (%)
 Breast 0 3 (50.0) 1 (16.7)
 Head and  necka 2 (28.6) 0 0
 Cervix 1 (14.3) 0 1 (16.7)
 Ovary 1 (14.3) 1 (16.7) 0
 Uterus 1 (14.3) 1 (16.7) 0
 Otherb 2 (28.6) 1 (16.7) 4 (66.7)
Time since metastatic diagnosis, years
 Median (min, max) 1.61 (0, 2.5) 4.60 (2.2, 9.3) 1.87 (0.9, 4.9)
Prior chemotherapy regimens, n (%)
 1 0 1 (16.7) 0
 2 2 (28.6) 0 1 (16.7)
 3 0 1 (16.7) 1 (16.7)
 4 1 (14.3) 0 0
 ≥ 5 4 (57.1) 4 (66.7) 4 (66.7)
Best response to prior cancer therapy, n (%)
 Partial response 3 (42.9) 2 (33.3) 3 (50.0)
 Stable disease 4 (57.1) 3 (50.0) 2 (33.3)
 Disease progression 0 1 (16.7) 1 (16.7)
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remained relatively stable over the 8-h sampling period, with 
the geometric mean plasma concentration at 8 h (C8h) being 
53–77% of the corresponding geometric mean Cmax values.
Systemic exposure to adavosertib increased in a slightly 
greater than dose-proportional manner as the adavosertib 
dose increased from 175 to 225 mg bid (Table 3). A 1.3-fold 
increase in adavosertib dose resulted in a 1.3- to 1.8-fold 
increase in geometric mean area under the plasma concen-
tration–time curve from time zero until the last quantifiable 
concentration (AUC 0–t).
Adavosertib accumulated in plasma after administration 
of multiple doses, with a geometric mean (coefficient of 
variation) accumulation ratio of 2.1 (38%) in cohort 1, 2.7 
(17%) in cohort 2, and 2.3 (15%) in cohort 1a.
No drug–drug interactions were observed for any of the 
agents administered in this study (Table 3 and Supplemen-
tary Tables S2 and S3).
3.4  Antitumor Activity
The best overall response observed was a partial response in 
one of six evaluable patients (16.7%) in both cohorts 1 and 
1a, and in three of six evaluable patients (50.0%) in cohort 2 
(Table 4). The overall median duration of response in these five 
patients was 20.7 weeks (95% confidence interval 18.1, not 
evaluable; Kaplan–Meier estimate). Stable disease occurred in 
two of six evaluable patients (33.3%) in each cohort.
4  Discussion
Results of Phase II studies indicate that adavosertib sensi-
tizes patients to chemotherapy [7, 12]. Adavosertib showed 
efficacy when combined with carboplatin in women with 
Table 2  Adverse events occurring with adavosertib and chemother-
apy
A175C adavosertib 175  mg + carboplatin, A175PC ada-
vosertib 175  mg + paclitaxel + carboplatin, A225PC adavosertib 
225  mg + paclitaxel + carboplatin, TEAE treatment-emergent adverse 
event, WBC white blood cell
a TEAE defined as any AE that occurred after administration of the 
first dose of study drug and through 28  days after the last dose of 
study drug, or any event that was present at baseline and continued 
after the first dose of study drug but worsened in intensity
b TEAEs occurring with an incidence of > 40% in any cohort
c None of the patients reported to have a decreased platelet count were 
also reported to have thrombocytopenia (n = 1 [14.3%] in cohort 1; 
n = 2 [33.3%] in cohort 2; n = 1 [16.7%] in cohort 1a)
d None of the patients reported to have a decreased neutrophil count 
were also reported to have neutropenia
e Grade ≥ 3 TEAEs occurring with an incidence of > 30% in any 
cohort
f None of the patients reported to have a decreased platelet count were 
also reported to have thrombocytopenia
Patients experiencing  TEAEsa, 
n (%)
Cohort 1 
(A175PC)
N = 7
Cohort 2 
(A225PC)
N = 6
Cohort 1a 
(A175C)
N = 6
TEAEsb 6 (85.7) 6 (100.0) 6 (100.0)
 Nausea 6 (85.7) 5 (83.3) 5 (83.3)
 Vomiting 6 (85.7) 5 (83.3) 4 (66.7)
 Anemia 6 (85.7) 5 (83.3) 4 (66.7)
 Diarrhea 5 (71.4) 5 (83.3) 3 (50.0)
 WBC count decreased 5 (71.4) 5 (83.3) 3 (50.0)
 Decreased appetite 4 (57.1) 2 (33.3) 4 (66.7)
 Platelet count  decreasedc 4 (57.1) 3 (50.0) 3 (50.0)
 Neutrophil count  decreasedd 3 (42.9) 3 (50.0) 4 (66.7)
 Pyrexia 3 (42.9) 4 (66.7) 1 (16.7)
 Neutropeniad 3 (42.9) 2 (33.3) 0
 Constipation 2 (28.6) 3 (50.0) 0
 Proctalgia 1 (14.3) 3 (50.0) 1 (16.7)
Grade ≥ 3  TEAEse 6 (85.7) 6 (100.0) 4 (66.7)
 Anemia 4 (57.1) 5 (83.3) 2 (33.3)
 WBC count decreased 5 (71.4) 5 (83.3) 1 (16.7)
 Platelet count  decreasedf 4 (57.1) 3 (50.0) 2 (33.3)
 Neutrophil count  decreasedd 3 (42.9) 3 (50.0) 2 (33.3)
 Neutropeniad 3 (42.9) 2 (33.3) 0
 Thrombocytopeniaf 1 (14.3) 2 (33.3) 1 (16.7)
 Febrile neutropenia 1 (14.3) 2 (33.3) 0
 Diarrhea 1 (14.3) 2 (33.3) 0
 Hypophosphatemia 1 (14.3) 2 (33.3) 0
 Sepsis 0 2 (33.3) 0
Treatment-related TEAEs 6 (85.7) 6 (100.0) 4 (66.7)
Serious TEAEs 3 (42.9) 4 (66.7) 0
Fatal TEAEs 1 (14.3) 1 (16.7) 0
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Cohort 1 (A175PC): Adavosertib 175 mg + paclitaxel 175 mg/m² + carboplatin AUC 5
Time (h)
Cohort 1a (A175C): Adavosertib 175 mg + carboplatin AUC 5
Cohort 2 (A225PC): Adavosertib 225 mg + paclitaxel 175 mg/m² + carboplatin AUC 5
Fig. 2  Semi-logarithmic plot showing the geometric mean (± stand-
ard deviation) plasma concentration–time profile for adavosertib 
on cycle 1, day 3*.bid twice daily; *Multiple doses of adavosertib 
175  mg bid with paclitaxel plus carboplatin (cohort 1), adavosertib 
225 mg bid with paclitaxel plus carboplatin (cohort 2), or adavosertib 
175 mg bid with carboplatin (cohort 1a)
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TP53-mutated ovarian cancer refractory or resistant to first-
line platinum-based chemotherapy, with sustained responses 
of over 30 months seen in two patients [7]. Adavosertib also 
showed activity in combination with single-agent chemo-
therapy (carboplatin, paclitaxel, gemcitabine, or pegylated 
liposomal doxorubicin) in women with primary platinum-
resistant ovarian cancer [12]. Results of these studies sup-
port a role for adavosertib in tumors that respond inade-
quately to chemotherapy.
This Phase Ib study investigated the optimal adavosertib 
dosage in Asian patients. Various factors, including race, 
affect drug pharmacokinetics. Differences observed between 
Western and Asian patients in exposure to some drugs may 
be attributable to factors such as body weight and drug 
metabolism [13, 14]. The recommended Phase II regimen of 
adavosertib for use in combination with paclitaxel and car-
boplatin in Western patients is 225 mg bid for 2.5 days [10].
This study investigated regimens of adavosertib 175 mg 
bid for 2.5 days in combination with carboplatin alone or 
with paclitaxel plus carboplatin, or adavosertib 225 mg bid 
for 2.5 days in combination with paclitaxel plus carboplatin. 
Pharmacokinetic analyses indicated that adavosertib was 
steadily absorbed and then slowly eliminated, and that co-
administration of paclitaxel and carboplatin had no appar-
ent effect on the pharmacokinetics of adavosertib. It should 
be noted that the terminal elimination phase of adavosertib 
could not be fully characterized because blood sampling was 
only conducted up to 8 h post-dose. Data suggest that expo-
sure of adavosertib was 30–45% higher in Asian patients in 
this study than in Western patients [8], which explains, at 
least in part, the tolerability findings. Additional investiga-
tion to better understand these differences is ongoing.
Adavosertib 175 mg bid was considered tolerable when 
administered for 2.5 days per 21-day cycle in combination 
with paclitaxel plus carboplatin, or with only carboplatin, 
in Asian patients. However, adavosertib 225 mg bid for 
2.5 days administered in combination with paclitaxel plus 
carboplatin was not considered tolerable, with two patients 
Table 3  Single-dose and multiple-dose pharmacokinetics of adavosertib
AUC 0–t area under the plasma concentration–time curve from time zero until the last quantifiable concentration, C8h plasma concentration at 8 h, 
Cmax maximum plasma concentration, CV coefficient of variation, Gmean geometric mean, tlast time to the last quantifiable concentration, tmax 
time to maximum plasma concentration
a Cycle 0, day 1: single dose of adavosertib 175 mg (cohorts 1 and 1a) or adavosertib 225 mg (cohort 2)
b Cycle 1, day 1: single dose of adavosertib 175 mg with paclitaxel plus carboplatin (cohort 1), single dose of adavosertib 225 mg with paclitaxel 
plus carboplatin (cohort 2), or single dose of adavosertib 175 mg with carboplatin (cohort 1a)
c Cycle 1, day 3: multiple doses of adavosertib 175 mg with paclitaxel plus carboplatin (cohort 1), multiple doses of adavosertib 225 mg with 
paclitaxel plus carboplatin (cohort 2), or multiple doses of adavosertib 175 mg with carboplatin (cohort 1a)
d N = 6 for AUC 0–t and  Cmax
e N = 4 for AUC 0–t and  Cmax
f N = 5 for AUC 0–t and  Cmax
Parameter Cycle 0, day  1a Cycle 1, day  1b Cycle 1, day  3c
Cohort 1 
(N = 7)d
Cohort 2 
(N = 6)
Cohort 1a 
(N = 5)e
Cohort 1 
(N = 6)f
Cohort 2 
(N = 6)
Cohort 1a 
(N = 6)f
Cohort 1 
(N = 6)
Cohort 2 
(N = 6)f
Cohort 1a 
(N = 6)
AUC 0–t, 
nM·h
 Gmean 3521 5331 3387 4191 5606 2902 8300 14,870 7154
 CV, % 44.91 37.42 12.54 34.89 20.02 33.21 32.85 34.05 32.29
Cmax, nM
 Gmean 689.1 1066 649.2 705.4 1133 654.8 1271 2289 1129
 CV, % 51.79 38 10.74 28.03 16.3 32.27 30.52 32.82 25.51
C8h, nM
 Gmean 370.1 612 343.5 446.6 805.9 378.2 982 1700 774.6
 CV, % 29.15 36.6 29.97 27.83 27.5 27.61 30.17 37.6 32.96
tmax, h
 Median 2.02 3.96 3.95 4.00 4.04 4.04 4.00 4.04 3.09
 Min, max 1.00, 8.00 1.00, 5.87 2.00, 8.00 0.95, 8.02 3.98, 6.00 4.00, 8.00 2.05, 4.08 1.00, 7.95 1.95, 4.08
tlast, h
 Median 8.00 8.00 7.98 8.01 8.03 7.65 7.96 7.98 7.98
 Min, max 7.83, 8.00 7.97, 8.02 7.20, 8.00 7.92, 8.17 7.95, 8.08 7.20, 8.00 7.85, 8.00 7.85, 8.15 7.20, 8.17
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experiencing DLTs (grade 4 sepsis and grade 5 acute res-
piratory distress syndrome). The event of acute respiratory 
distress syndrome was considered by the investigator to be 
possibly related to adavosertib and paclitaxel; other poten-
tial contributing factors included the patient’s underlying 
disease (metastatic lung cancer), prior chemotherapy and 
radiotherapy, and possible infection. Dose escalation in the 
cohort receiving adavosertib with only carboplatin was not 
evaluated in this study.
The tolerability profile of adavosertib 175 mg bid for 
2.5 days plus chemotherapy in this study was generally 
similar to that reported in Western women who received 
adavosertib 225 mg bid for 2.5 days plus chemotherapy [7, 
8]. For example, the most commonly reported TEAEs (all 
grades) were fatigue (87% of patients), nausea (78%), diar-
rhea (70%), thrombocytopenia (70%), and anemia (61%) in 
women with ovarian cancer refractory or resistant to first-
line platinum-based chemotherapy who received adavosertib 
plus carboplatin in the PN009 study [7]. In women with 
platinum-sensitive ovarian cancer who received adavosertib 
in combination with paclitaxel and carboplatin in the PN004 
study, the most commonly reported AEs (all grades) were 
nausea (78%), diarrhea (75%), vomiting (63%), alopecia 
(54%), and fatigue (54%) [8]. In this study, fatigue was 
reported in 28.6%, 16.7%, and 33.3% of patients in cohorts 
1, 2, and 1a, respectively.
Preliminary assessment of adavosertib in combination 
with paclitaxel plus carboplatin or with only carboplatin 
indicated antitumor activity in heavily pre-treated Asian 
patients with advanced solid tumors. However, the small 
number of patients in each treatment group meant that no 
firm conclusions could be drawn regarding differences in 
tumor response endpoints. In addition to small patient num-
bers, interpretation of the duration of response is limited by 
the fact that patients were not followed up for progression 
after discontinuation of treatment.
Although adavosertib 225 mg bid for 2.5 days demon-
strated antitumor activity, based on the tolerability findings, 
adavosertib 175 mg bid for 2.5 days was chosen as the rec-
ommended Phase II dose in combination with paclitaxel and 
carboplatin in Asian patients.
In terms of other adavosertib trials, results of Phase I 
studies indicate that combination therapy with adavosertib 
plus olaparib [15] or durvalumab [16] had a manageable 
tolerability profile in patients with advanced solid tumors. 
A Phase I study also demonstrated that adavosertib in com-
bination with neoadjuvant docetaxel and cisplatin had an 
acceptable tolerability profile in patients with advanced head 
and neck squamous cell carcinoma [17]. Ongoing studies 
in Asian patients include a Phase II study (NCT02593019) 
evaluating the efficacy of adavosertib monotherapy in Asian 
patients with relapsed small-cell lung cancer.
5  Conclusions
In Asian patients, the recommended Phase II dose of ada-
vosertib (175 mg bid for 2.5 days per 21-day cycle in com-
bination with paclitaxel plus carboplatin) is lower than the 
recommended Phase II dose in Western patients, most likely 
reflecting the increased exposure of adavosertib in Asian 
versus Western patients. Preliminary assessment of ada-
vosertib in combination with paclitaxel plus carboplatin or 
Table 4  Antitumor activity of adavosertib in combination with chemotherapy
A175C adavosertib 175 mg + carboplatin, A175PC adavosertib 175 mg + paclitaxel + carboplatin, A225PC adavosertib 225 mg + paclitaxel + car-
boplatin, CI confidence interval, NE not evaluable
a Confirmed complete response or partial response
b Confirmed complete response, partial response, or stable disease
c Kaplan–Meier estimates
Cohort 1 (A175PC)
N = 6
Cohort 2 (A225PC)
N = 6
Cohort 1a (A175C)
N = 6
Best overall response, n (%)
 Complete response 0 (0) 0 (0) 0 (0)
 Partial response 1 (16.7) 3 (50.0) 1 (16.7)
 Stable disease 2 (33.3) 2 (33.3) 2 (33.3)
 Progressive disease 2 (33.3) 0 (0) 1 (16.7)
 Not evaluable 1 (16.7) 1 (16.7) 2 (33.3)
Objective  responsea, n (%) 1 (16.7) 3 (50.0) 1 (16.7)
Clinical  benefitb, n (%) 3 (50.0) 5 (83.3) 3 (50.0)
Median duration of  responsec, weeks (95% CI) 18.1 (NE, NE) 20.7 (NE, NE) NE (NE, NE)
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with only carboplatin indicated antitumor activity in Asian 
patients with advanced solid tumors.
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